-
Mashup Score: 18
The drug was 88% effective against the need for medical attention among those in their second respiratory virus season.
Source: www.cidrap.umn.eduCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 18
The drug was 88% effective against the need for medical attention among those in their second respiratory virus season.
Source: www.cidrap.umn.eduCategories: General Medicine News, Infectious DiseaseTweet-
#Nirsevimab 89% effective against #RSV hospitalization for babies, CDC estimates The drug was 88% effective against the need for medical attention among those in their second respiratory virus season. https://t.co/fAOYXVGsZ8 https://t.co/F887KTwEPk
-
-
Mashup Score: 5Access to highly effective long-acting RSV-monoclonal antibodies for children in LMICs—reducing global inequity - 4 month(s) ago
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection (LRTI), hospitalisation, and mortality in infants and young children, with the highest burden of severe disease in low-income and middle-income countries (LMICs).1 The predominant burden of hospitalisation occurs in full-term healthy infants younger than 6 months; however, preterm infants are also at risk of severe RSV-LRTI up to the age of 2 years2 as are children with underlying chronic conditions such as congenital heart disease, lung disease of prematurity, or immunodeficiency.
Source: www.thelancet.comCategories: General Medicine News, General HCPsTweet-
RT @julienpotet: New @LancetGH op-ed on access to #nirsevimab for #RSV in LMICs. https://t.co/sx1pmBDqlL Very clear infographic in the Sup…
-
-
Mashup Score: 1
The program allows participants to reserve doses and be eligible for priority shipping, among other benefits.
Source: www.contagionlive.comCategories: General Medicine News, Infectious DiseaseTweet-
#Nirsevimab reservation enrollment deadline has passed, limited ordering will become available for the #RSV monoclonal antibody. https://t.co/H2OIQTAiFQ https://t.co/GfcN6yP0SB
-
-
Mashup Score: 2Nirsevimab is 90% Effective Against RSV-Associated Hospitalizations - 8 month(s) ago
Though a small number of infants received nirsevimab in the analysis, results support existing nirsevimab recommendations to prevent serious RSV disease in infants.
Source: www.contagionlive.comCategories: General Medicine News, Infectious DiseaseTweet-
Though a small number of infants received nirsevimab in the analysis, results support existing #nirsevimab recommendations to prevent serious #RSV disease in infants. https://t.co/hBHVwVx1LY
-
-
Mashup Score: 157
A monoclonal antibody for universal respiratory syncytial virus prophylaxis in infants has recently been licensed. We share our experiences of integrating nirsevimab into the regional immunisation programme in Galicia, Spain. After a 3-week hospital-based immunisation campaign with flexible individualised appointments and educational activities, nirsevimab uptake was 97.5% in the high-risk group, 81.4% in the catch-up group and 92.6% in infants born during the campaign. This successful implementation strategy can serve as a model and may inform other countries’ programmatic deliberations.
Source: www.eurosurveillance.orgCategories: General Medicine News, Infectious DiseaseTweet-
Nearly 93% of babies born in Galicia, Spain this fall were given #nirsevimab (Beyfortus), the monoclonal antibody that protects against severe #RSV, in a clearly successful hospital-based distribution program. US supplies have been severely constrained. https://t.co/NbcQ5ic90r
-
#Nirsevimab 89% effective against #RSV hospitalization for babies, CDC estimates The drug was 88% effective against the need for medical attention among those in their second respiratory virus season. https://t.co/fAOYXVGsZ8 https://t.co/F887KTwEPk